- Home
- FLNC vs AKRO Comparison
FLNC vs AKRO Comparison
Compare FLNC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- AKRO
- Stock Information
- Founded
- FLNC 2018
- AKRO 2017
- Country
- FLNC United States
- AKRO United States
- Employees
- FLNC N/A
- AKRO N/A
- Industry
- FLNC Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- AKRO Health Care
- Exchange
- FLNC Nasdaq
- AKRO Nasdaq
- Market Cap
- FLNC 2.4B
- AKRO 2.1B
- IPO Year
- FLNC 2021
- AKRO 2019
- Fundamental
- Price
- FLNC $22.01
- AKRO $31.59
- Analyst Decision
- FLNC Buy
- AKRO Strong Buy
- Analyst Count
- FLNC 17
- AKRO 7
- Target Price
- FLNC $27.35
- AKRO $43.20
- AVG Volume (30 Days)
- FLNC 1.3M
- AKRO 441.5K
- Earning Date
- FLNC 11-26-2024
- AKRO 11-11-2024
- Dividend Yield
- FLNC N/A
- AKRO N/A
- EPS Growth
- FLNC N/A
- AKRO N/A
- EPS
- FLNC N/A
- AKRO N/A
- Revenue
- FLNC $2,143,395,000.00
- AKRO N/A
- Revenue This Year
- FLNC $27.28
- AKRO N/A
- Revenue Next Year
- FLNC $44.10
- AKRO N/A
- P/E Ratio
- FLNC N/A
- AKRO N/A
- Revenue Growth
- FLNC 7.87
- AKRO N/A
- 52 Week Low
- FLNC $12.74
- AKRO $11.36
- 52 Week High
- FLNC $27.80
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- FLNC 53.21
- AKRO 66.34
- Support Level
- FLNC $20.00
- AKRO $29.34
- Resistance Level
- FLNC $21.65
- AKRO $32.15
- Average True Range (ATR)
- FLNC 0.96
- AKRO 1.26
- MACD
- FLNC -0.08
- AKRO 0.10
- Stochastic Oscillator
- FLNC 65.79
- AKRO 99.74
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.